GLOBAL — October 20, 2026 -- No blood test can tell you today whether ketamine will work for your depression. A 2026 Molecular Psychiatry study by Jones GH, Gilbert JR, Johnston JN and colleagues points to immune markers that may one day help.
The team compared four compounds: ketamine, its metabolite hydroxynorketamine (HNK), LSD and psilocybin. Ketamine blocks NMDA receptors in the glutamate system. LSD and psilocybin act mainly on serotonin receptors. The question was whether drugs that start in different places end up changing the same things inside neurons.
Ketamine and the psychedelics changed 103 proteins in common
The researchers treated lab-grown human neurons with each compound and tracked gene activity. The neurons were made from stem cells donated by people with treatment-resistant depression and by healthy volunteers. They then compared the results with proteins in the cerebrospinal fluid of healthy volunteers who had received intravenous ketamine.
In total, 103 proteins changed after ketamine and after at least one of the lab compounds. According to the researchers, 86% of them were also affected by at least one psychedelic. That works out to about 89 proteins (103 × 0.86). Roughly 14 matched only ketamine or HNK.
Two areas stood out. One was immune signaling, with the molecules IL-15 and MCP-1 near the center. The other was insulin signaling and neuroplasticity, meaning the brain's ability to reorganize its connections.
Responders showed different immune patterns before their ketamine infusion
The patient data came from people with treatment-resistant depression and healthy volunteers who received a single intravenous ketamine infusion or a placebo. Before treatment, people who later responded had lower IL-15 activity and more B-cell signaling activity than nonresponders. After ketamine, those patterns reversed.
- A higher MCP-1 to IL-7 ratio was associated with a poorer response.
- A higher IL-4 to interferon gamma ratio was associated with a better response.
The researchers say the findings are exploratory and not ready for clinical use
The limits are specific. The lab neurons came from female donors only. The cerebrospinal fluid data came from healthy volunteers, not people with depression. Different measurements were taken at different times after ketamine. The investigators say larger, independent studies are needed before clinical use. The write-up does not give the number of patients in the response analysis.
This account comes from a post by David Mahjoubi, an anesthesiologist at NutraBrain Clinic, not from the paper itself. He says patients should not ask for IL-15 or IL-7 tests expecting a prediction. His post also states that the research does not change how ketamine is prescribed today.